Regulatory, diagnostic, and therapeutic roles of microRNAs in chronic liver diseases.

IF 1.3 4区医学 Q4 GASTROENTEROLOGY & HEPATOLOGY

Acta gastro-enterologica Belgica Pub Date : 2024-07-01 DOI:10.51821/87.2.12965

Razieh Kazemzadeh, Maryam Kheirollahi, Seyed Ali Mard, Akram Ahangarpour, Feryal Savari

{"title":"Regulatory, diagnostic, and therapeutic roles of microRNAs in chronic liver diseases.","authors":"Razieh Kazemzadeh, Maryam Kheirollahi, Seyed Ali Mard, Akram Ahangarpour, Feryal Savari","doi":"10.51821/87.2.12965","DOIUrl":null,"url":null,"abstract":"<p><p>Fibrogenesis is initially performed during tissue damage to protect the remaining tissues from the progressive death of epithelial cells, infiltration of immune and inflammatory cells, and local degrading enzymes. Inflammation can lead to excessive extracellular matrix deposition by fibroblasts and the induction of fibrosis in many organs, such as the liver. MiRNAs are small noncoding RNAs that mediate mRNA repression or destabilization, leading to translational repression. Owing to the wide range of roles of miRNAs in the development of fibrosis, especially liver fibrosis, many studies have focused on their diagnostic, regulatory, and therapeutic roles. In this study, we used medical science and general databases, including PubMed, Elsevier, Scopus, Nature, and Google Scholar, to find valid studies on the different roles of miRNAs in liver fibrosis. Because a large number of miRNAs with regulatory, diagnostic, and therapeutic roles in diseases associated with liver fibrosis have been identified and reported in this study, special attention to these elements is needed in the future of healthcare systems.</p>","PeriodicalId":7322,"journal":{"name":"Acta gastro-enterologica Belgica","volume":null,"pages":null},"PeriodicalIF":1.3000,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta gastro-enterologica Belgica","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.51821/87.2.12965","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Fibrogenesis is initially performed during tissue damage to protect the remaining tissues from the progressive death of epithelial cells, infiltration of immune and inflammatory cells, and local degrading enzymes. Inflammation can lead to excessive extracellular matrix deposition by fibroblasts and the induction of fibrosis in many organs, such as the liver. MiRNAs are small noncoding RNAs that mediate mRNA repression or destabilization, leading to translational repression. Owing to the wide range of roles of miRNAs in the development of fibrosis, especially liver fibrosis, many studies have focused on their diagnostic, regulatory, and therapeutic roles. In this study, we used medical science and general databases, including PubMed, Elsevier, Scopus, Nature, and Google Scholar, to find valid studies on the different roles of miRNAs in liver fibrosis. Because a large number of miRNAs with regulatory, diagnostic, and therapeutic roles in diseases associated with liver fibrosis have been identified and reported in this study, special attention to these elements is needed in the future of healthcare systems.

查看原文本刊更多论文

微小核糖核酸在慢性肝病中的调节、诊断和治疗作用。

纤维生成最初是在组织受损时进行的，以保护剩余组织免受上皮细胞逐渐死亡、免疫和炎症细胞浸润以及局部降解酶的影响。炎症可导致成纤维细胞过度沉积细胞外基质，并诱导肝脏等许多器官纤维化。MiRNA 是小型非编码 RNA，可介导 mRNA 抑制或不稳定，从而导致翻译抑制。由于 miRNAs 在纤维化（尤其是肝纤维化）的发展过程中起着广泛的作用，许多研究都聚焦于它们的诊断、调控和治疗作用。在本研究中，我们使用了医学科学和通用数据库，包括 PubMed、Elsevier、Scopus、Nature 和 Google Scholar，以查找有关 miRNA 在肝纤维化中不同作用的有效研究。由于本研究发现并报道了大量在肝纤维化相关疾病中具有调节、诊断和治疗作用的 miRNA，因此未来的医疗系统需要特别关注这些内容。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Acta gastro-enterologica Belgica Medicine-Gastroenterology

CiteScore

2.30

自引率

20.00%

发文量

期刊介绍： The Journal Acta Gastro-Enterologica Belgica principally publishes peer-reviewed original manuscripts, reviews, letters to editors, book reviews and guidelines in the field of clinical Gastroenterology and Hepatology, including digestive oncology, digestive pathology, as well as nutrition. Pure animal or in vitro work will not be considered for publication in the Journal. Translational research papers (including sections of animal or in vitro work) are considered by the Journal if they have a clear relationship to or relevance for clinical hepato-gastroenterology (screening, disease mechanisms and/or new therapies). Case reports and clinical images will be accepted if they represent an important contribution to the description, the pathogenesis or the treatment of a specific gastroenterology or liver problem. The language of the Journal is English. Papers from any country will be considered for publication. Manuscripts submitted to the Journal should not have been published previously (in English or any other language), nor should they be under consideration for publication elsewhere. Unsolicited papers are peer-reviewed before it is decided whether they should be accepted, rejected, or returned for revision. Manuscripts that do not meet the presentation criteria (as indicated below) will be returned to the authors. Papers that go too far beyond the scope of the journal will be also returned to the authors by the editorial board generally within 2 weeks. The Journal reserves the right to edit the language of papers accepted for publication for clarity and correctness, and to make formal changes to ensure compliance with AGEB’s style. Authors have the opportunity to review such changes in the proofs.